IRIS
LAPADULA, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.347
AS - Asia 5.485
EU - Europa 4.915
SA - Sud America 1.571
Continente sconosciuto - Info sul continente non disponibili 671
AF - Africa 198
OC - Oceania 9
Totale 29.196
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.124
SG - Singapore 2.341
IT - Italia 1.430
CN - Cina 1.262
BR - Brasile 1.220
SE - Svezia 714
HK - Hong Kong 674
FR - Francia 662
RU - Federazione Russa 528
DE - Germania 482
VN - Vietnam 378
FI - Finlandia 312
GB - Regno Unito 266
UA - Ucraina 195
IN - India 167
BD - Bangladesh 144
AR - Argentina 128
CA - Canada 96
IQ - Iraq 86
MX - Messico 64
BE - Belgio 62
ID - Indonesia 59
PK - Pakistan 53
IE - Irlanda 52
CO - Colombia 51
EC - Ecuador 51
ZA - Sudafrica 51
TR - Turchia 50
ES - Italia 38
JP - Giappone 36
SA - Arabia Saudita 36
VE - Venezuela 35
MA - Marocco 30
CI - Costa d'Avorio 27
PL - Polonia 25
CL - Cile 24
NL - Olanda 24
PH - Filippine 24
UZ - Uzbekistan 24
PY - Paraguay 23
AT - Austria 21
EG - Egitto 21
IR - Iran 18
TN - Tunisia 18
CZ - Repubblica Ceca 16
LT - Lituania 16
AZ - Azerbaigian 15
JM - Giamaica 15
MY - Malesia 15
PE - Perù 13
KE - Kenya 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 10
CR - Costa Rica 10
NP - Nepal 10
BO - Bolivia 9
DK - Danimarca 9
DZ - Algeria 9
ET - Etiopia 9
JO - Giordania 9
EU - Europa 8
OM - Oman 8
HN - Honduras 7
RS - Serbia 7
AL - Albania 6
AU - Australia 6
IL - Israele 6
NI - Nicaragua 6
TH - Thailandia 6
BY - Bielorussia 5
CH - Svizzera 5
HR - Croazia 5
KG - Kirghizistan 5
KZ - Kazakistan 5
LB - Libano 5
PA - Panama 5
QA - Qatar 5
RO - Romania 5
AO - Angola 4
BG - Bulgaria 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
KR - Corea 4
MD - Moldavia 4
MN - Mongolia 4
PS - Palestinian Territory 4
PT - Portogallo 4
SY - Repubblica araba siriana 4
BB - Barbados 3
BH - Bahrain 3
GE - Georgia 3
GF - Guiana Francese 3
GR - Grecia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
DM - Dominica 2
EE - Estonia 2
Totale 28.493
Salva come PNG Salva come JPEG
Città #
Fairfield 1.879
Woodbridge 1.473
Ashburn 1.420
Singapore 1.264
Houston 1.196
Chandler 1.068
San Jose 801
Seattle 798
Ann Arbor 748
Cambridge 683
Hong Kong 670
Milan 620
Wilmington 607
Nyköping 550
Jacksonville 539
Beijing 363
Council Bluffs 285
Lawrence 245
Roxbury 245
Dallas 229
Nanjing 225
Lauterbourg 222
New York 212
Rome 199
Des Moines 149
Los Angeles 148
Inglewood 146
Princeton 136
Santa Clara 117
Ho Chi Minh City 113
Munich 108
São Paulo 103
Boardman 101
Bari 99
San Diego 88
Helsinki 84
Dearborn 81
Hanoi 79
London 71
Shenyang 65
Brooklyn 62
Brussels 62
Moscow 62
Columbus 59
Buffalo 56
Figino 56
Paris 55
Dublin 51
Hebei 50
Chicago 47
Nanchang 44
Rio de Janeiro 42
Turku 42
Jiaxing 39
Baghdad 38
Redwood City 35
San Francisco 34
Tokyo 33
Belo Horizonte 32
Changsha 32
Frankfurt am Main 32
The Dalles 31
Tianjin 31
Turin 31
Bar Harbor 29
Boston 29
Jakarta 29
Abidjan 26
Falkenstein 26
Nuremberg 26
Toronto 26
Denver 25
Atlanta 24
Montreal 24
Orem 24
Brasília 23
Dong Ket 23
Guangzhou 23
Lahore 23
Tashkent 23
Warsaw 23
Quito 22
Dhaka 20
Johannesburg 20
Campinas 19
Naples 19
Da Nang 18
Hefei 18
Chennai 17
Guayaquil 17
Poplar 17
Shanghai 17
Augusta 16
Jinan 16
Mumbai 16
Phoenix 16
Jeddah 15
Manchester 15
Stockholm 15
Washington 15
Totale 20.039
Salva come PNG Salva come JPEG
Nome #
Safety of Long-Term Biologic Therapy in Rheumatologic Patients With a Previously Resolved Hepatitis B Viral Infection 210
Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors 210
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 200
No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan 197
Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease 195
A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab 193
Adalimumab in the treatment of immune-mediated diseases 188
AB0618 A unique ultrasound pattern of adipose tissue in systemic sclerosis patients: a comparison with rheumatoid arthritis patients and healthy controls. two sides of adipose tissue involvement in systemic chronic inflammatory diseases 187
AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease 187
A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy 185
AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1 182
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease 180
Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients 180
Early changes of articular cartilage, synovial membrane and subchondral bone in an experimental model of goat osteoarthrtitis 179
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 178
Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study 174
Papular-purpuric gloves and socks syndrome due to parvovirus B19: a report of two simultaneous cases in cohabitant families 173
Retinal vessels thrombosis as onset manifestation of systemic sclerosis: 3 clinical cases 173
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 172
Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA 171
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives 171
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: Premises, perils, and perspectives 170
Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies 170
Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: A case series and review of the literature 168
SAT0216 Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings 168
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register 166
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis 166
Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis 165
Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy 165
Orofacial Manifestations and Temporomandibular Disorders of Sjogren Syndrome: An Observational Study 164
ANTI-TNFA THERAPY IN PSORIATIC ARTHRITIS: DIFFERENT RATE OF REMISSION IN POLYARTICULAR AND OLIGOARTICULAR SUBSETS 160
Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab 158
Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response 157
Leucocytoclastic vasculitis as onset symptom of ulcerative colitis 155
Orofacial Manifestations and Temporomandibular Disorders of Systemic Scleroderma: An Observational Study. 154
Different switching rate of anti-TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life 153
AN UNWELCOME HOST IN THE PATHOGENESIS OF ARTHRITIDES 152
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study 152
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 150
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine 149
Serum cartilage oligomeric matrix protein (COMP) following infliximab treatment in patients with rheumatoid arthritis: Analitical performances and clinical correlations 148
SAT0212 Pericardial Effusion Related To Systemic Sclerosis: A Possible Contribution of The Serum Levels of Adipokines and Interleukines 148
Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis 147
Old and new antirheumatic drugs and the risk of hepatotoxicity 147
ASSOCIATION OF SYSTEMIC SCLEROSIS AND PSORIATIC ARTHRITIS: A CASE REPORT 146
LIPID PROFILE OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ANTI-TNF-ALPHA DRUGS CHANGES ACCORDING TO DISEASE ACTIVITY RESPONSE 146
Joint and tendon involvement predict disease progression in systemic sclerosis: A EUSTAR prospective study 145
Intra-articular therapy with tumor necrosis factor-α antagonists: An update 144
Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa 144
Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features 144
Serum amyloid-A in Behçet's disease 143
The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper 142
Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings 142
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 142
Analysis of subchondral cortical plate and trabecular bone in osteoarthritis experimentally induced in goat tibia. Preliminary results 141
Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab 141
PRESENT STATUS AND NEW PERSPECTIVES IN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS THERAPY 141
PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists 140
Management of Small Vessel Vasculitides 137
Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: A multicenter randomized clinical trial 137
FRI0110 Methotrexate monotherapy in real life: a drug survival analysis. comparison between very early arthritis and early arthritis cohorts 136
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register 135
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 135
Evaluation of Serum Levels of Adipokines and Interleukines in Pericardial Effusion Related to Systemic Sclerosis 135
Obesity and Inflammation – Targets for OA Therapy 134
Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature 134
Different joint and skin clinical response of patients with psoriatic arthritis treated with infliximab 134
Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: International recommendations 133
Untangling the web of systemic autoinflammatory diseases 133
). Analysis of subchondral cortical plate and trabecular bone in osteoarthritis experimentally induced in goat tibia. Preliminary results. 131
Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register) 131
Update on the profile of the EUSTAR cohort: An analysis of the EULAR Scleroderma Trials and Research group database 130
AB0245 PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE) 130
OP0129 Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors 130
Improvement of Refractory Dysphagia in Patients with Idiopathic Inflammatory Myopathies Receveing Immunoglobulin Intravenous Therapy 130
Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA 129
ISOLATED STERNOCLAVICULAR JOINT ARTHRITIS IN HEROIN ADDICTS AND/OR HIV POSITIVE PATIENTS: THREE CASES 127
Prevalence of anti-CCP antibodies in systemic sclerosis 127
Giant Cell Tumor of Synovial Sheath: Of Two Cases Treated with Intra-Articular Infiltration of Infliximab 126
The pathophysiology of osteoarthritis 125
Anti-cyclic citrullinated peptide autoantibodies measured by an automated enzyme immunoassay: analytical performance and clinical correlations 125
Sarcoidosis presenting with Raynaud's syndrome: a case report 124
GISEA: an Italian biological agents registry in rheumatology 124
Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies 124
Isolated thrombocytopenia associated with low dose methotrexate therapy 123
Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid 123
Digital laser doppler flowmetry may discriminate "limited" from "diffuse" systemic sclerosis 123
Intentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritis 123
EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR) 122
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 122
THU0168 Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis 120
Efficacy and safety of certolizumab pegol in rheumatoid arthritis: Meeting rheumatologists' requirements in routine clinical practice 119
A CASE OF SWEET'S SYNDROME WITH RHEUMATIC ONSET 118
Response of cartilage oligomeric matrix protein to monoclonal antibody drugs in patients with rheumatoid arthritis 118
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE) 118
Cutaneous lesions as presenting symptoms of primary biliary cirrhosis: an undifferentiated connective tissue disease-like onset 117
CHONDROCYTES-ECM INTERACTIONS IN HUMAN OSTEOARTHRITIS In: Mallia C., Uitto J. (eds) Rheumaderm. Advances in Experimental Medicine and Biology, vol 455. Springer, Boston, MA 117
MONOCLONAL ANTIBODY INVESTIGATION IN RHEUMATOID ARTHRITIS: PRESENCE OF A T CELL SUBPOPULATION BEARING A DOUBLE MARKER 116
THE INHIBITOR OF COSTIMULATION OF T CELLS: ABATACEPT 116
PHENOTYPING OF CHONDROCYTES FROM HUMAN OSTEOARTHRITIC CARTILAGE: CHONDROCYTE EXPRESSION OF BETA INTEGRINS AND CORRELATION WITH ANATOMIC INJURY 115
Totale 14.824
Salva come PNG Salva come JPEG
Categoria #
all - tutte 122.228
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.228
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.463 0 0 23 111 87 118 85 102 102 112 293 430
2022/20232.808 435 326 192 265 321 358 58 287 449 19 59 39
2023/2024758 77 174 32 55 49 176 17 43 3 33 12 87
2024/20253.723 63 65 342 103 56 311 275 391 165 216 576 1.160
2025/20268.281 1.138 384 472 969 918 454 944 271 716 714 185 1.116
2026/2027859 194 363 302 0 0 0 0 0 0 0 0 0
Totale 29.196